ImmixBio and BeiGene to evaluate combination of IMX-110 and Tislelizumab in solid tumors

Latest Pharma News Update

Immix Biopharma, Inc. announced a clinical trial and supply agreement with BeiGene, Ltd. to evaluate the safety, tolerability and efficacy of combining IMX-110, a Tissue-Specific Therapeutic with TME Normalization Technology, with BeiGene’s anti-PD-1 antibody Tislelizumab, for the treatment of various solid tumors, in the U.S. and internationally.

Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.

“ImmixBio is proud to showcase our Tissue-Specific Therapeutics (TSTx)™ platform to the world. Promising data from our ongoing IMX-110 clinical trial, from pre-clinical studies in a genetic mouse model of pancreatic cancer showing IMX-110 turning “cold” tumours “hot,” and IMX-110 in combination with murine anti-PD-1 demonstrating extended survival in a genetic mouse model of pancreatic cancer versus multi-drug combinations in the literature, have demonstrated substantial rationale to combine IMX-110 and tislelizumab,” said Ilya Rachman, MD, PhD – ImmixBio CEO. “We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions.”

About IMX-110

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumour micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumour blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumour-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumour and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumour apoptosis, a non-inflammatory tumour-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumour progression).

IMX-110 is currently being evaluated in a phase 1b/2a open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study in patients with advanced solid tumors in the United States and Australia.

About Tislelizumab

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of the antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumour and hematologic cancers.

The China National Medical Products Administration (NMPA) has granted tislelizumab market authorization in four indications, including full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Tislelizumab is not approved for use outside of China.

In January 2021, BeiGene and Novartis entered into a collaboration and license agreement granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

Tags : #Immixbio #Beigene #Tislelizumab #SolidTumours #IMX110 #Novartis

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Actor-Director Sathish Kaushik Died of a Heart Attack at the Age of 66March 09, 2023
Soleus Push-Ups: A Laziest Exercise to Lower Blood Sugar LevelsMarch 09, 2023
World Kidney Day 2023: Be Aware of Kidney DiseasesMarch 09, 2023
Sushmita Sen reveals about suffering from a severe heart attack recently and Addison's disease in 2014March 06, 2023
A significant increase in influenza A H3N2 patients that are accompanied by severe coughing and feverMarch 06, 2023
Is AIDS or HIV curable in Ayurveda?March 03, 2023
Artificial Sweetener Erythritol Raises the Possibility of Heart Attack.March 01, 2023
Difference between HIV and AIDS - When to give antiretroviral therapy?March 01, 2023
Zero Discrimination Day: Let's Raise the Voice Against DiscriminationMarch 01, 2023
International Women’s Day 2023 – Embrace EquityFebruary 28, 2023
Brain Tumors - Types, Symptoms and Risk FactorsFebruary 28, 2023
World Rare Disease Day: End Stigma Against Rare Diseases.February 28, 2023
National Science Day 2023 - Global Science for Global WellbeingFebruary 28, 2023
Eating disorders - Types and their complicationsFebruary 27, 2023
The condition that took away the life of Malayalam filmmaker, Joseph ManuFebruary 27, 2023
World NGO Day 2023 - We make a living by what we get, but we make a life by what we giveFebruary 27, 2023
Functions and Problems of SerotoninFebruary 25, 2023
Arthritis management – Tips to manage arthritis effectivelyFebruary 25, 2023
Apple has undertaken a project of no-prick blood sugar monitoring feature for its watch.February 24, 2023
Bird flu – Jharkhand on alert, know its prevention and symptoms in humansFebruary 24, 2023